Protocols

Important Disclaimer: The information below describes protocols reported in research literature and is not personalized medical advice. TB-500 is not approved by regulatory agencies for human therapeutic use. Any use should only occur under proper medical supervision and in accordance with applicable laws and regulations.

The available evidence on TB-500 (Thymosin Beta-4) dosing protocols is extremely limited. Most published research focuses on detection methods for anti-doping purposes rather than therapeutic protocols.

Research Context

TB-500 is described in the literature as a synthetic version of an active region of thymosin β₄, specifically the N-terminal acetylated 17-23 fragment. The compound has been identified primarily in the context of potential doping in athletic settings rather than established therapeutic applications.

Limited Protocol Information

The available literature does not provide comprehensive dosing protocols for TB-500. One ongoing clinical trial (NCT07487363) is investigating TB-500 for cardiovascular biomarkers in stable atherosclerotic cardiovascular disease, but specific dosing details from this Phase 1/2 trial are not yet published.

Evidence Limitations

The current evidence base has significant gaps:

No established therapeutic dosing guidelines in peer-reviewed literature
Limited human clinical data on safety and efficacy
Most research focuses on analytical detection rather than clinical protocols
The compound lacks regulatory approval for human therapeutic use

Safety Considerations

Given the limited safety and efficacy data, any consideration of TB-500 use should involve:

Consultation with qualified healthcare providers
Understanding of regulatory status and legal considerations
Awareness that evidence for therapeutic benefits remains preliminary

The absence of well-documented protocols in the scientific literature reflects the early stage of research into this compound's potential therapeutic applications.

TB-500 (Thymosin Beta-4)

Member access required